Feed AKBLF
AK
ALK-Abelló A/S AKBLF OTC · Healthcare · Denmark
$36.50 +0.00% +$0.00
Depth
- Market cap
- 49.8B kr
- Enterprise value
- 48.5B kr
- P/E
- 36.8x
- Forward P/E
- 32.9x
- PEG
- 0.9x
- P/S
- 7.3x
- P/FCF
- 26.4x
- EV/EBITDA
- 22.3x
- ROIC
- 16.1%
- Gross margin
- 68.0%
- Net margin
- 19.9%
- Dividend yield
- 0.68%
- Payout ratio
- 25.1%
- Net debt/EBITDA
- -0.6x
- Beta
- 0.71
- Free float
- 60.1%
Sector
Healthcare
Industry
Biotechnology
CEO
Peter Halling
Employees
2,721
Headquarters
Horsholm
Valuation
Is today's price reasonable?
- What to watch: You pay 36.8 DKK for 1 DKK of yearly profit, a lot for its sector.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Revenue grew by 12% a year over the last 3 years.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: Out of every 100 DKK of revenue, 20 DKK is left as net profit.
- What speaks for it: It earns 16 DKK a year on every 100 DKK of invested capital.
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: 1.73B kr against 420.5M kr.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number